Mirabegron vs Oxybutynin for Women: Memory, BP, Cost

Published on October 23, 2026 — by Ellen Bennett, Women’s Health Researcher

Medical & Affiliate Disclosure: This article is for educational purposes only and is not medical advice. Do not stop, start or switch any prescription on your own. Bring these questions to your doctor or pharmacist. Some links are affiliate links; if you buy through them we may earn a commission at no extra cost to you.

Independent women's health research · Written and fact-checked by Ellen Bennett, Women's Health Researcher · Last verified: October 2026

If your doctor has suggested a pill for an overactive bladder, there is a good chance the shortlist came down to two names: oxybutynin, the old, inexpensive standard, and mirabegron, sold as Myrbetriq and now also as a generic. Maybe you were handed one and read something worrying about it. Maybe you are on oxybutynin already and wondering whether mirabegron vs oxybutynin is a conversation worth having.

It usually is, especially for women past 60. The two drugs work through completely different pathways, and that difference shows up in exactly the places older women care about most: memory, dry mouth, constipation and blood pressure. This guide lays out what the research says on each, without pretending either drug is perfect, so you can have a better conversation at your next appointment.

How Each Drug Works

Oxybutynin: blocking the “squeeze” signal

Oxybutynin is an antimuscarinic (anticholinergic) drug. It blocks acetylcholine, the chemical messenger that tells the bladder muscle to contract, so the bladder squeezes less often and less urgently. The problem is that acetylcholine does many jobs in the body: it helps make saliva and tears, keeps the gut moving, and plays a role in memory. Oxybutynin enters the brain more easily than some other drugs in its class, which is why it attracts the most concern.

Mirabegron: relaxing the bladder wall

Mirabegron is a beta-3 adrenergic agonist. Instead of blocking a signal, it switches on receptors in the bladder wall that help it relax and hold more urine as it fills. It does not block acetylcholine, so it avoids the classic anticholinergic side effects. Its own trade-off is cardiovascular: it can raise blood pressure. A second beta-3 drug, vibegron (Gemtesa), works the same way.

Mirabegron vs Oxybutynin Side by Side

	Oxybutynin	Mirabegron
Drug class	Antimuscarinic (anticholinergic)	Beta-3 agonist
Dry mouth	Common; the main reason people stop	At placebo level in pooled trials
Constipation	Common	Low
Memory concern	Linked to higher dementia risk with long-term use	Lower than anticholinergics in most studies; one 2025 study found a link
Blood pressure	Not a main concern	Can rise; monitoring advised; not recommended with severe uncontrolled hypertension
Key drug interactions	Other anticholinergic drugs add up	Moderate CYP2D6 inhibitor (e.g., metoprolol, some heart rhythm drugs)
Forms	Tablets (immediate and extended release), skin patch, gel	Extended-release tablet
Cost	Inexpensive generic	Generic available in the US since 2024; brand Myrbetriq costs more; coverage varies

Dry Mouth and Constipation: What the Trials Show

The cleanest numbers come from a 2013 pooled analysis of three phase III trials in the International Journal of Clinical Practice, which included 4,611 people with overactive bladder, about 72% of them women, with an average age around 59. Over 12 weeks, dry mouth was reported by:

• 2.1% on placebo
• 1.7% on mirabegron 50 mg
• 10.1% on tolterodine, an antimuscarinic used as the comparison

That comparison drug was tolterodine, not oxybutynin, so it is not a direct head-to-head. But the authors note that earlier trials of antimuscarinic drugs reported dry mouth in anywhere from 9% to 93% of patients, and oxybutynin, especially the immediate-release form, is known as one of the drier options. Dry mouth sounds minor until it is every day, and it is the most common reason people quit these drugs.

If dryness is already part of your life, for example with Sjögren's, this difference matters even more. In a small 2023 randomized trial in Sjögren's patients, 6 of 17 switched off an anticholinergic bladder drug because of dry mouth or constipation, while none of the 24 on mirabegron switched.

Memory and Dementia: The Honest Version

This is the question that sends most women searching, so here is the full picture, including the part that complicates it.

Study	Who	Finding
JAMA Internal Medicine, 2019	58,769 people with dementia vs 225,574 controls, England	Heavy use of bladder antimuscarinics (about 3+ years of daily doses) linked to 65% higher odds of dementia
BMJ Medicine, 2024	170,742 people with dementia aged 55+ vs 804,385 without	Oxybutynin used for more than a year linked to 28 to 31% higher risk; results for mirabegron were mixed
International Journal of Urology, 2026	3,794 Japanese women aged 65 to 84	49% higher dementia risk on anticholinergics than on beta-3 agonists (hazard ratio 1.49); no difference in frailty or care needs
World Journal of Urology, 2025	941,402 patients with overactive bladder, US network data	Most anticholinergics and mirabegron linked to higher dementia risk vs untreated patients; only fesoterodine was not

That last row is important, and most articles about mirabegron leave it out. It does not mean mirabegron is as risky as oxybutynin. Studies like these compare people who were prescribed medicine with people who were not, and the treated group may differ in many ways: more severe symptoms, more other illnesses, or earlier use of anticholinergic drugs before switching. The 2026 study that compared the two drug types directly in older women, which is the fairer comparison, still favored beta-3 drugs. But it is a reminder that “non-anticholinergic” is not the same as “proven risk-free”, and that the safest pill is often the one you do not need.

The guidelines have caught up with the anticholinergic signal. The 2024 AUA/SUFU guideline asks clinicians to discuss dementia risk with patients on antimuscarinics, and the 2023 American Geriatrics Society Beers Criteria list strongly anticholinergic drugs among those people with dementia or cognitive impairment should avoid. I go deeper into the oxybutynin side in oxybutynin and dementia.

Blood Pressure: Mirabegron's Real Trade-Off

Mirabegron's prescribing information warns that it can raise blood pressure, advises periodic monitoring, especially in people with hypertension, and says it is not recommended for people with severe uncontrolled hypertension. Canada's label goes further and defines that as a top number of 180 or above or a bottom number of 110 or above. The patient summary on MedlinePlus covers the same warnings.

How often does it actually matter? In the pooled trials above, hypertension was reported as a side effect at almost identical rates: 7.6% on placebo, 7.5% on mirabegron 50 mg and 8.1% on tolterodine. In real-world use, a 2025 study in Cureus followed 46 women with well-controlled hypertension who took mirabegron for overactive bladder. Most improved, and 3 of the 46 had a rise in blood pressure; in each case mirabegron was simply stopped. The authors suggest home blood pressure monitoring to catch that small group early.

Vibegron (Gemtesa), the other beta-3 drug, is described by its maker as the only one in its class without a blood pressure warning on its label, and an ambulatory blood pressure study found no clinically significant change at the standard dose, according to its safety information. It is worth asking about if blood pressure is your main concern, though cost and coverage vary.

What About Women Over 80?

The oldest women are the ones most sensitive to anticholinergic side effects, and they are often the ones taken off these drugs by other doctors. A 2023 study looked at 42 women over 80 who had been stopped from anticholinergic drugs and switched to mirabegron 50 mg. After 12 weeks, frequency, nighttime trips, urgency and total symptom scores were all significantly lower than before. It was a small, retrospective study with no comparison group, but it shows that stopping an anticholinergic does not have to mean giving up treatment.

Mirabegron vs Oxybutynin: Which Might Suit You?

If this describes you	The conversation leans toward
Over 65, or any memory concerns in you or your family	Avoiding strong anticholinergics like oxybutynin where possible
Already taking other anticholinergic drugs (some sleep aids, older antihistamines, some antidepressants)	A non-anticholinergic option, to avoid adding to the total load
Dry mouth, dry eyes or constipation already a problem	Mirabegron or vibegron
High blood pressure that is not well controlled	Not mirabegron until it is controlled; ask about vibegron or non-drug options
Taking metoprolol, flecainide, propafenone or other CYP2D6-sensitive drugs	A pharmacist check before mirabegron
Cost is the deciding factor	Ask whether generic mirabegron is covered, and about lower-risk antimuscarinics such as trospium

Questions worth asking out loud: Do I still need this medicine at my current dose? Would a beta-3 drug suit my blood pressure? What is my total anticholinergic load across all my prescriptions? How should I switch safely if we decide to? My guide to medications that cause bladder leaks helps you list everything before the appointment.

Before Any Pill: What Works Alongside or Instead

The 2024 AUA/SUFU guideline recommends offering bladder training to everyone with overactive bladder, and it has no side effects at all. Many women need less medication, or none, once it is working. Start with:

• Bladder training: gradually stretching the time between trips. My bladder training schedule gives you a week-by-week plan.
• Urge control: when the urge hits, stop, stand still, do a few quick pelvic floor squeezes, and walk calmly once it eases. See stress vs urge incontinence to confirm which type you have.
• Fluids and irritants: steady fluids earlier in the day and less caffeine; see how much water to drink with an overactive bladder.
• Night trips: if waking at night is the main issue, the causes are often different; see nocturia in women.

Where Supplements Fit, Honestly

No supplement has been shown to match either drug for an overactive bladder, and none should replace a prescription without your doctor's input. For pure urgency with no infections, the supplement ingredient with the best evidence is Urox, which beat placebo in a 2018 randomized trial; I review it in Urox for bladder control.

Where a microbiome formula fits is narrower: if your urgency comes with urinary infections that keep returning, especially since menopause. FemiCore combines cranberry standardized to 30% proanthocyanidins with five named Lactobacillus strains, and none of its ingredients is anticholinergic. It does not treat overactive bladder and is not a substitute for medication, but it can be part of the plan if infections are in the picture. My FemiCore review covers the evidence and its limits.

Key Takeaways

• Different pathways: oxybutynin blocks acetylcholine; mirabegron relaxes the bladder through beta-3 receptors.
• Dry mouth: 1.7% on mirabegron vs 2.1% on placebo and 10.1% on the antimuscarinic comparator in pooled trials of 4,611 people.
• Memory: anticholinergics carry the stronger dementia signal; a 2026 study of older women found 49% higher risk than with beta-3 drugs.
• But not zero: a 2025 study of 941,402 patients also linked mirabegron to dementia vs untreated patients, likely partly due to who gets treated.
• Mirabegron's trade-off is blood pressure: monitor it, and avoid mirabegron with severe uncontrolled hypertension.
• Never switch on your own, and start bladder training whatever you decide.

Frequently Asked Questions

Is mirabegron safer than oxybutynin?

For many older women it has fewer side effects. Mirabegron is not anticholinergic, causes dry mouth at about placebo level in trials, and a 2026 study of women aged 65 to 84 found lower dementia risk than with anticholinergics. But it can raise blood pressure, and one 2025 study linked it to dementia compared with untreated patients. The safer choice depends on your health.

Does mirabegron cause dementia?

The evidence is mixed. Most studies find a weaker or no dementia signal for mirabegron compared with anticholinergic drugs, but a 2025 study of 941,402 patients found an association compared with untreated patients. That type of study cannot separate the drug from differences in who gets treated, so it shows a link, not proof.

Why is oxybutynin linked to dementia?

Oxybutynin blocks acetylcholine, a chemical messenger involved in memory, and it crosses into the brain more easily than some similar drugs. A 2024 BMJ Medicine study found oxybutynin used for more than a year was associated with a 28 to 31% higher dementia risk.

Can mirabegron raise blood pressure?

Yes. Its prescribing information warns that it can increase blood pressure, advises monitoring, and says it is not recommended for severe uncontrolled hypertension. In pooled trials, hypertension was reported at similar rates on mirabegron and placebo, and in a 2025 study 3 of 46 women with controlled hypertension had a rise.

Can I switch from oxybutynin to mirabegron?

Many people do, but only with your doctor. Ask whether mirabegron suits your blood pressure and other medications, how to make the switch, and whether you still need medication at all once bladder training is in place. Do not stop oxybutynin on your own.

Is there a natural alternative to oxybutynin?

Bladder training is the most effective non-drug option and is recommended for everyone with overactive bladder. Among supplements, Urox has a placebo-controlled trial for urgency and frequency. No supplement has been shown to match prescription drugs, so talk to your doctor before changing anything.

The Bottom Line

Mirabegron vs oxybutynin is not a choice between a good drug and a bad one. It is a choice between two sets of trade-offs. Oxybutynin is cheap and effective but blocks acetylcholine everywhere, which shows up as dry mouth, constipation and a dementia signal that grows with years of use. Mirabegron avoids those, but asks you to watch your blood pressure, and it is not proven risk-free. For most women over 60, the evidence and the guidelines lean away from strong anticholinergics where there is a reasonable alternative. Take this to your doctor, ask the questions above, and keep bladder training going whatever you choose.

— Ellen Bennett

Further reading: the complete guide to bladder leaks, oxybutynin and dementia and menopause and bladder health.